|
|
||||||||
Vol. 273, Issue 4, C1427-C1434, October 1997
1 Department of Medicine, Hôpital St.-Luc, Université de Montréal, Montreal, Quebec H2X 3J4; 2 Institut de Recherche Clinique de Montréal, Université de Montréal, Montreal, Quebec H2W 1R7; and 3 Department of Medicine, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada H3A 1A1
| |
ABSTRACT |
|---|
|
|
|---|
In our previous studies, we found that the atrial natriuretic peptide (ANP) binding and guanylyl cyclase activity of A-type natriuretic peptide receptors (NPR-A) were upregulated in renal papillae but downregulated in vascular tissues and glomeruli of rats with deoxycorticosterone acetate (DOCA)-salt hypertension [E. Nuglozeh, G. Gauquelin, R. Garcia, J. Tremblay, and E. L. Schiffrin. Am. J. Physiol. 259 (Renal Fluid Electrolyte Physiol. 28): F130-F137, 1990]. To further understand the molecular significance of these regulations, we measured the relative abundance of the transcripts of NPR-A and NPR-B by Northern blot in the aorta, mesenteric arteries, adrenal cortex, renal papillae, and lungs in DOCA-salt hypertensive and control rats. In renal papillae we also examined the translation and transcription of NPR-A by ribosome loading and run-on assay. Compared with controls, the steady-state levels of mRNA for NPR-A were increased in the aorta and mesenteric arteries but were decreased in the adrenal cortex and renal papillae in DOCA-salt-treated rats. NPR-B mRNA was decreased in the aorta, mesenteric arteries, and adrenal cortex in hypertensive rats. In lungs the mRNA for both receptors was unchanged. Translation of NPR-A mRNA, as assessed by ribosome loading, was reduced in renal papillae. Transcriptional activity of its gene was not detectable in these tissues. Guanosine 3',5'-cyclic monophosphate levels generated by NPR-A in renal papillae and by NPR-A and NPR-B in the adrenal cortex, aorta, and mesenteric arteries of DOCA-salt-treated rats remained increased in hypertension. The higher NPR-A activity in the presence of a lower level of its mRNA in renal papillae and the higher NPR-B activity in the presence of a lower level of its mRNA in the vasculature, adrenal cortex, and lungs can alternatively be explained by receptor stabilization or increased receptor recycling.
Northern blot; deoxycorticosterone acetate; recycling
| |
INTRODUCTION |
|---|
|
|
|---|
THE FAMILY OF atrial natriuretic peptides (ANPs) comprises at least three peptides: atrial natriuretic peptide (ANP) (8), brain natriuretic peptide (7), and C-type natriuretic peptide (CNP) (12). The most dramatic hemodynamic and renal effects of these peptides are vasodilation, increased natriuresis, and diuresis, which combine to produce vasorelaxation and reduction in blood pressure (10, 11). In the kidney, ANP increases glomerular filtration (5), but the natriuresis appears to be predominantly mediated by distal tubular receptors (21). ANP receptors have been found in the glomerulus (4) and in the renal papilla (3), where they are present on vasa recta and collecting ducts (3). ANP stimulates guanosine 3',5'-cyclic monophosphate (cGMP) accumulation in a large number of tissues, including glomeruli (2) and medullary and papillary collecting duct cells (17), an effect produced through the activation of particulate guanylyl cyclase (16). Binding studies, Northern blot studies, and enzymatic studies have demonstrated the presence of ANP receptor mRNA and cGMP generation in vascular tissues and vascular smooth muscle cells (30, 33). Subsequently, it has been reported that vascular smooth muscle cells produce CNP, which may have autocrine functions on these cells (13). Membrane preparations from other organs, e.g., adrenals and lungs, avidly bind ANP with dissociation constants of 30-1,800 pM (16) and 6.5-660 pM, respectively (12). Molecular cloning studies have identified three different natriuretic peptide receptors (NPRs) (8, 12, 28). Two of these receptors, NPR-A and NPR-B, also called GC-A and GC-B, constitute a newly described family of receptor guanylyl cyclase. These receptors are single transmembrane proteins with extracellular domains that share 44% identity. The intracellular regions of these proteins can be divided into two domains. The first domain of NPR-A and NPR-B, which is 280 amino acids long, is 30% homologous to protein kinase. The COOH-terminal portion, which is ~250 amino acids long, is the guanylyl cyclase catalytic domain, which is activated on binding of the appropriate natriuretic peptide to the extracellular domain. This catalytic region exhibits the highest amount of sequence identity (88%) between NPR-A and NPR-B.
The third member of the NPR family is NPR-C. Molecular cloning (12) showed that this receptor contains a very short 37-amino acid cytoplasmic tail that bears no homology to the intracellular domain of any other known receptor. Its intracellular domain, however, is ~30% identical to that of NPR-A and NPR-B and is negatively coupled to adenylate cyclase (1).
The three NPR subtypes recognize the three known natriuretic peptides differentially. ANP and brain natriuretic peptide can effectively stimulate NPR-A, whereas NPR-B is efficiently stimulated by CNP (18, 19). NPR-C binds all three known natriuretic peptides with high affinity in assuming clearance and buffering functions (20).
Studying deoxycorticosterone acetate (DOCA)-salt hypertensive rats, we previously showed an increase in the number of receptors and cGMP responses to ANP in renal papillae of DOCA-salt hypertensive rats but a downregulation of ANP receptors in glomeruli and mesenteric arteries (22). From the former studies, it seems that NPR regulation is tissue specific; therefore, we undertook this study to determine the molecular aspect of this regulation in different tissues of this animal model.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials.
All materials were of the highest reagent grade available.
Tris(hydroxymethyl)aminomethane (Tris) · HCl, Triton
X-100, glycerol, diethyl pyrocarbonate, dithiothreitol, proteinase K,
ammonium acetate, bovine serum albumin, and DOCA were from Sigma
Chemical (St. Louis, MO); guanidine thiocyanate, sucrose (ribonuclease free), and 3-(N-morpholino)propanesulfonic acid from
Research Organic (Cleveland, OH); sodium dodecyl sulfate (SDS),
N,N,N',N'-tetramethylenediamine, acrylamide, bisacrylamide, EDTA, ethylene glycol-bis(
-aminoethyl ether)-N,N,N',N'-tetraacetic
acid, NaCl, MgCl2, KCl, KOH, NaOH,
-mercaptoethanol, agarose, formaldehyde, sodium lauryl sarcosine, sodium citrate, and deoxycholate from Fisher (Nepean, ON, Canada); formamide, rNTP, dNTP, ribonuclease A, and yeast tRNA from Boehringer Mannheim (Laval, PQ, Canada); and
-UTP and
-ATP from Amersham (Oakville, ON, Canada). X-Omat XRP6 film was from Eastman Kodak (Rochester, NY). Taq DNA polymerase was from Cetus.
Synthetic rat ANP-(99
126) was purchased from Institut Armand-Frappier
(Laval, PQ, Canada).
Animal experiments. DOCA-salt hypertension was induced by the method of Ormsbee and Ryan (23). Male Sprague-Dawley rats (Charles River Laboratories, St.-Constant, PQ, Canada) weighing 200 g were uninephrectomized under isoflurane anesthesia. Silicone rubber impregnated with 130 mg DOCA/rat was implanted, and rats were given 1% saline to drink. A group of 20 hypertensive rats were studied 5-6 wk after the intervention, a period previously shown to be sufficient for development of hypertension. Another group of uninephrectomized rats was implanted with silicone rubber without DOCA impregnation and served as controls. This group received tap water to drink. In an attempt to dissociate the role of DOCA, salt, and uninephrectomy, rats were submitted to procedures that were unlikely to allow the complete pattern of hypertension to appear. Sixteen rats underwent sham uninephrectomy, which consisted of anesthesia and laparotomy without removal of kidney tissue. These rats did not receive DOCA and drank tap water. A second group of animals (n = 20) underwent uninephrectomy but were not exposed to DOCA or NaCl. DOCA was administered to 15 uninephrectomized rats that received regular tap water to drink. The last group of rats (n = 16) underwent uninephrectomy and drank water to which 1% NaCl was added, but they did not receive DOCA. The large number of animals studied was necessary to provide sufficient tissue samples for molecular biology studies. Animal experiments were reviewed and accepted by our institution's animal experiments ethics board.
Blood pressure was measured 5-6 wk after the initial procedure. In our experience, this length of time is sufficient for hypertension to develop in the vast majority of DOCA-salt-treated rats. The rats were anesthetized with isoflurane. A right carotid PE-50 catheter was inserted. The rats were allowed to recover, and blood pressure was measured the next morning using an American Optical blood pressure monitor (model 1331A). The rats were then killed, and tissues were quickly harvested and frozen in liquid nitrogen for Northern blot and ribosome-loading studies.cGMP generation by renal papillae, mesenteric arteries, aorta, and
adrenal cortex in response to ANP and CNP stimulation.
Rat papillae from different experimental groups were dissected, minced,
and subjected to digestion with collagenase (2 mg/ml). After 2 h of
digestion, the papillae were totally disrupted, the cells were washed
twice, and their viability was evaluated by trypan blue exclusion. The
papillae were resuspended in Krebs buffer with the following
composition (mmol/l): 118 NaCl, 1.18 MgSO4, 1.18 KH2PO4,
5.5 dextrose, 25.0 NaHCO3, 2.5 CaCl2, and 4.7 KCl. The solution
was bubbled with 95% O2-5%
CO2. The cells were preincubated
with 0.5 mmol/l 1-isobutyl-3-methylxanthine for 10 min to inhibit
phosphodiesterase activity, then stimulated with increasing
concentrations of ANP (10
12
to 10
6 mol/l) for 10 min.
The reaction was quenched with 1 meq/l trichloroacetic acid, and cGMP was determined by radioimmunoassay after acetylation. The adrenal cortex was prepared from the whole adrenal by removal of
the medulla. Each tube, containing 50 mg of mesenteric arteries, aorta,
and adrenal cortex slices of control and DOCA-salt-treated rats, was
incubated with increasing concentrations of ANP and CNP. On the next
day, the tissue slices were soaked in liquid nitrogen and quickly
ground using Varimix (model 3, Caulk Dentsply Division International,
Toronto, ON, Canada). The powdered tissues were resuspended in the same
liquid used for stimulation, and cGMP generation was measured as
previously described.
ANP receptor probe preparation.
Polymerase chain reaction (PCR) analysis was performed on rat genomic
DNA with primers designed in 3'-untranslated region in the
primary structure of rat guanylyl cyclase A/ANP receptor gene (32) to
avoid cross hybridization between receptors of the same family. The
sense and antisense primers were GCAAAGGCAAGGTTCGGACCTATTGGC and
TGTCCTCTTCGTTCCATTGGCCGTCGA, respectively. PCR was performed on a
Perkin-Elmer/Cetus DNA thermal cycler with Perkin-Elmer/Cetus Taq DNA polymerase. Amplification was performed in 100-µl
reactions with 100 ng of rat genomic DNA and 100 pmol each 27-mer
oligonucleotide primer, 1 mmol/l each dGTP, dATP, dCTP, and dTTP, 10%
dimethyl sulfoxide, 67 mmol/l Tris · HCl, pH 8.8, 6.7 mM MgCl2, 6.7 mmol/l EDTA, 10 mmol/l
-mercaptoethanol, and 0.17 mg/ml bovine serum albumin, with 1 U of Taq DNA polymerase. The reaction was initially subjected to heating for 1 min at 94°C, then 30 cycles of 30 s at
94°C, 30 s at 59°C, and 30 s at 72°C. The PCR product
yielded a fragment of 554 base pairs, which was cloned into the plasmid pSP72 and confirmed by sequencing. NPR-B was a gift from Garber Laboratory.
Northern blot analysis of NPR-A and NPR-B mRNA.
Total RNA was extracted by guanidine and phenol methods, as previously
described (9). Total RNA (10 µg), denatured with formaldehyde and
electrophoresed in 1% agarose gels (35% formaldehyde) in
3-(N-morpholino)propanesulfonic acid buffer, was
transferred to a Zetaprobe membrane. The RNA was cross-linked onto the
membrane using the ultraviolet cross-linker FB-UVXL-1000. The membrane was prehybridized for 2 h at 69°C in a sodium phosphate-SDS buffer (400 mmol/l) containing 60% formamide and hybridized overnight in the
same buffer to a high-specific-activity cRNA probe (~3 × 109
counts · min
1 · µg
1
RNA). The filters were washed in 0.1% SDS-1 mmol/l EDTA at
70-80°C and autoradiographed at
80°C with Kodak XAR
film and an intensifier screen. Exposures varied from 6 to 12 h. The
integration was monitored using an imaging densitometer (model GS-670,
Bio-Rad). Chicken 18S ribosomal cDNA probe was used as an internal
standard.
Polysome and monosome purification.
Renal papillae (0.5-1 g) from each group of rats were homogenized
in 6 ml of HKM buffer (250 mmol/l sucrose, 50 mmol/l
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, pH 7.5, 100 mmol/l potassium acetate, 5 mmol/l magnesium acetate,
5 mmol/l
-mercaptoethanol, 0.5 mg/ml heparin) containing 0.5%
Triton-X, 300 U/ml RNasin, and 10 mM ethylene glycol-bis(
-aminoethyl ether)-N,N,N',N'-tetraacetic
acid at 4°C with 10 strokes of a motor-driven Teflon-glass
homogenizer. The nuclei were pelleted by centrifugation at 4,000 revolutions/min (rpm) for 5 min. The supernatants were adjusted to
0.1% Nonidet P-40 and 0.1% deoxycholate and recentrifuged for 15 min
at 15,000 rpm. The postmitochondrial fractions were loaded on 2 mol/l
sucrose and centrifuged in Quick-Seal tubes (Polyallomer, Beckman) in a
70.1 Ti rotor at 65,000 rpm for 90 min at 4°C. The polysome pellets
were suspended in HKM buffer, and absorbance (ratio of optical density
at 260 nm to optical density at 280 nm) was >1.5.
RNA extraction. SDS was added to a final concentration of 0.5% to each sucrose fraction, and each fraction was extracted four times with an equal volume of 1:1 phenol-chloroform and twice with chloroform. Escherichia coli tRNA carrier (10 µg) was added to each fraction, concentrated by two precipitations with ethanol, and dissolved in 10 mmol/l Tris · HCl and 1 mmol/l EDTA, pH 8.
Statistics. Values are means ± SE. Comparisons of changes in normalized steady-state mRNA levels and cGMP generation between two groups were made by Friedman's F test. Comparisons between two groups of rats were made by Student's t-test. Differences were considered significant at P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Ninety percent of DOCA-salt-treated rats were hypertensive (systolic blood pressure >160 mmHg). Only hypertensive rats were studied. The mean arterial blood pressure was 220 ± 2 mmHg (n = 20). All other groups of rats had significantly lower blood pressures (Table 1). The group of rats exposed to DOCA without saline was borderline hypertensive, with a mean systolic blood pressure of 133 ± 4 mmHg.
|
Expression of NPR-A mRNA in tissues from DOCA-salt-treated rats. In a first series of experiments, we measured NPR-A mRNA levels by Northern blot analysis in vascular tissues, lungs, adrenal cortex, and renal papillae of DOCA-salt-treated and control rats. The levels were dramatically increased in mesenteric arteries (to 520%) and in aorta (to 160%) in DOCA-salt-treated rats compared with controls. In renal papillae and adrenal cortex, the mRNA levels were lower in DOCA-salt-treated rats (Fig. 1). In lung tissues, NPR-A mRNA levels were similar in DOCA-salt-treated and control rats.
|
Expression of NPR-B mRNA in tissues from DOCA-salt-treated rats. NPR-B mRNA levels were studied in the same tissues. In DOCA-salt-treated and control rats, NPR-B mRNA was not measurable in the renal papillae. In the aorta, mesenteric arteries, and adrenal cortex, mRNA levels were significantly lower in hypertensive animals (Fig. 2). No significant difference was observed in lung tissue.
|
Comparative levels of NPR-A and NPR-B mRNA in tissues from DOCA-salt-treated and control rats. The ratios of mRNA for the two receptors were compared by analyzing the same amounts of RNA with probes of similar length, guanylyl cyclase content, and specific activities. The results are summarized in Fig. 3. In the aorta NPR-A mRNA was four times NPR-B mRNA in control rats; that difference was increased twofold in hypertensive rats. In mesenteric arteries, NPR-B mRNA was four times NPR-A mRNA. Hypertension reversed this ratio, with the level of NPR-A mRNA being threefold higher. In the adrenal cortex, as in the aorta, NPR-A mRNA was about four times higher than NPR-B mRNA; this ratio was not significantly changed by hypertension. In the lungs the ratio of the two receptors was nearly identical in normal and hypertensive rats.
|
Polysomal and monosomal profile analysis of rat renal papilla mRNA. To determine the translational status of NPR-A mRNA, polysomes and monosomes from Nonidet P-40-lysed tissues were isolated, and their RNA was analyzed by Northern blot. The experiment revealed an important reduction in full-length NPR-A mRNA molecules in DOCA-salt-treated rats, as demonstrated by the degradation smear with the monosomal and polysomal fractions that are between and beyond the two subunits of the ribosomes (Fig. 4).
|
cGMP generation by rat isolated tissues. NPR-A and NPR-B are guanylyl cyclases. In all the tissues studied, including renal papillae, mesenteric arteries, aorta, and adrenal cortex, cGMP generation in response to stimulation with ANP and CNP was significantly higher in DOCA-salt-treated rats than in controls (Figs. 5-7). This increase occurred at ANP and CNP concentrations endogenously observed in the DOCA-salt hypertensive animals (22).
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The initial purpose of this study was to understand the molecular mechanisms responsible for the upregulation of NPR-A in the renal papillae of DOCA-salt-treated rats observed in our previous studies. The results appear to contradict our initial findings: NPR-A mRNA is decreased in renal papillae in this model compared with control animals (Fig. 1). In addition, whereas NPR-A binding appeared suppressed in vascular tissues in DOCA-salt-treated rats (27), NPR-A mRNA is increased in these tissues. To further our understanding of this paradox, we undertook transcription and translation studies. We were unable to determine any variation at the level of transcription, since no transcription of the NPR-A gene was detectable by run-on assay conducted with renal papilla nuclei of control as well as DOCA-salt-treated rats (data not shown). The translation study demonstrates a decrease in NPR-A mRNA levels in polysomal as well as monosomal fractions (Fig. 4), an indication that this mRNA becomes susceptible to degradation in DOCA-salt-treated rats independent of its utilization by the translational machinery. The results of Northern blot studies are in total agreement with the ribosome-loading studies. How can the upregulation of NPR-A in the renal papillae in DOCA-salt-treated rats be explained in light of these transcription and translation studies?
To explain the paradox between the lower levels of NPR-A mRNA as demonstrated by Northern blot analysis and the ribosome-loading studies and our previous studies in which we showed that the binding and cGMP production were higher in renal papillae of DOCA-salt-treated rats than control rats, one must postulate that although the biosynthesis of NPR-A may be decreased, the half-life and activity of these receptors may be prolonged. Indeed, Hughes et al. (15) demonstrated that ANP receptor recycling occurred at 37°C in a rabbit carotid cell line but not at 4°C. Subsequently, Pandey (24, 25) conducted elegant studies on the kinetics and stoichiometry of internalization and recycling of ANP receptors in smooth muscle cells and murine Leydig tumor cells. This author demonstrated that a population of ANP receptors rapidly recycled (half-life = 5 min) from intracellular compartments to the plasma membrane. The apparent upregulation of ANP binding we observed in renal papillae of DOCA-salt hypertensive rats could be due to receptor recycling; i.e., even if the overall levels of translatable mRNA are decreased, the protein produced may be significantly less catabolized and is constantly mobilized through the recycling process. The factors that may induce this putative increase in NPR-A recycling in DOCA-salt-treated rats compared with controls remain unknown. In vitro, the mechanisms of recycling are influenced by temperature, the energy-depleting dinitrophenol and lysosomotropic agents like chloroquine (6), which are known to interfere with the intracellular routing, and the redistribution of the ligand-receptor complex (29). In vivo, in DOCA-salt-treated rats, there may be induction of some protein factors that can direct NPRs through the recycling machinery.
The regulation of NPR-A in DOCA-salt-treated rats is tissue specific. The mRNA levels are increased in the aorta and mesenteric arteries, whereas they are decreased in renal papillae and adrenal cortex. In mesenteric arteries the increase in mRNA correlated with an increase in cGMP generation, despite decreased NPR-A binding (22). This discrepancy may reflect a distribution and an activity of the receptor particular to this tissue and remains to be clarified. For example, in human umbilical vein endothelial cells, the constitutive form of nitric oxide synthase activity is increased, whereas its mRNA is decreased, suggesting that enzyme-specific activity, rather than enzyme quantity, was increased (26).
This differential regulation of the same mRNA in DOCA-salt hypertension is probably due to one or several factors differentially induced in tissues. It is possible that regulatory factors induced in renal papillae and the adrenal cortex at the onset of the hypertension are not expressed in the aorta and mesenteric arteries or vice versa. For example, it has been shown that, in some pathological states, RNA-binding proteins are expressed that trigger a rapid degradation of specific mRNA (34). Conversely, mRNA-stabilizing proteins may be produced that induce a net increase in the steady state of some mRNA. This concept of differential regulation of mRNA stability in DOCA-salt-treated rats may best explain our observations in the various tissues examined in this study.
Unlike NPR-A mRNA, NPR-B mRNA seems to be downregulated in all tissues examined, including the aorta, mesenteric arteries, adrenal cortex, and lungs (Fig. 2). Whether transcriptional or translational regulations are involved in these changes could not be verified in this study because of difficulties in obtaining good-quality nuclei and polysomes from these tissues. The NPR-B mRNA was undetectable in renal papillae in DOCA-salt-treated and control rats, obviating the ability to perform transcriptional and translational studies. However, on a molecular basis, NPR-B mRNA is intrinsically unstable because of the presence of two canonic sequences AUUUA in its 3'-untranslated region between nucleotides 3230 and 3235 as well as nucleotides 3237 and 3242 that induce destabilization and degradation in mRNA molecules (28). This may explain the decrease in NPR-B mRNA levels in DOCA-salt-treated rats (Fig. 2).
The fact that the NPR-B mRNA levels are decreased in the vascular tissues (aorta and mesenteric arteries) and adrenal cortex of DOCA-salt-treated rats leads to a second paradox. Whereas tissues from control rats, which contain more NPR-B mRNA, have low guanylyl cyclase activity, tissues from DOCA-salt-treated rats, which contain less mRNA, have a higher level of the enzymatic activity (cf. Figs. 2 and 7). In the aorta and mesenteric arteries, NPR-A and NPR-B are regulated in opposite directions. This may be linked to different regulatory cis elements present in the genes or their mRNA. The trans factors expressed in these tissues during hypertension might selectively or differentially affect the regulation of the receptor genes, leading to downregulation of the NPR-B mRNA and upregulation of NPR-A mRNA.
In conclusion, the present study demonstrates that, in DOCA-salt-treated rats, despite an upregulation of guanylyl cyclase activity of the NPR-A in renal papillae and NPR-B in the aorta and mesenteric arteries, the steady-state level of their mRNA is decreased. In the case of the NPR-A mRNA, this is probably due to destabilization by factors induced during the hypertension. To explain our findings, we postulate that NPR-A in renal papillae of DOCA-salt-treated rats are recycled, as are NPR-B in vascular tissues. However, further studies are necessary for molecular identification of these factors and, therefore, their functional significance in the pathophysiology of DOCA-salt hypertension.
| |
ACKNOWLEDGEMENTS |
|---|
We are indebted to Dr. G. Thibault for cGMP production determination.
| |
FOOTNOTES |
|---|
This study was supported in part by a grant from Fond de Recherche en Santé du Québec.
Address for reprint requests: E. Nuglozeh, The Jackson Laboratory, 600 Main St., Bar Harbor, ME 04609-1500.
Received 5 December 1996; accepted in final form 6 June 1997.
| |
REFERENCES |
|---|
|
|
|---|
1.
Anand-Srivastava, M.,
and
M. Cantin.
Atrial natriuretic factor receptors are negatively coupled to adenylate cyclase in cultured atria and ventricular cardiocytes.
Biochem. Biophys. Res. Commun.
138:
427-436,
1986[Medline].
2.
Ballerman, B. J.,
R. L. Hoover,
M. J. Karnowski,
and
M. Brenner.
Physiologic regulation of atrial natriuretic peptide receptors in rat glomeruli.
J. Clin. Invest.
76:
2049-2056,
1985.
3.
Bianchi, C.,
M. Ballak,
J. Gutkowska,
C. Charbonneau,
J. Genest,
and
M. Cantin.
Localization of 125I-atrial natriuretic factor (ANF) binding site in rat renal medulla. A light and electron microscopic radio-autographic study.
J. Histochem. Cytochem.
35:
149-153,
1987[Abstract].
4.
Bianchi, C.,
J. Gutkowska,
G. Thibault,
R. Garcia,
J. Genest,
and
M. Cantin.
Localization of atrial natriuretic factor and angiotensin II binding site in the glomerulus.
Am. J. Physiol.
251 (Renal Fluid Electrolyte Physiol. 20):
F594-F602,
1986.
5.
Carmago, M. J. F.,
H. D. Kleinert,
S. A. Atlas,
J. E. Sealay,
J. H. Laragh,
and
T. Maack.
Ca-dependent hemodynamic and natriuretic effects of atrial natriuretic extract in isolated rat kidney.
Am. J. Physiol.
246 (Renal Fluid Electrolyte Physiol. 15):
F447-F456,
1984.
6.
Carpenter, G.,
and
S. Cohen.
Binding, internalization and degradation of atrial natriuretic peptide in human fibroblast.
J. Cell Biol.
71:
159-171,
1976
7.
Chang, M. S.,
D. G. Lowe,
M. Lewis,
R. Hellmiss,
E. Chen,
and
D. V. Goeddel.
Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases.
Nature
341:
68-72,
1989[Medline].
8.
Chinkers, M.,
D. L. Garbers,
M. S. Chang,
D. G. Lowe,
H. Chin,
D. V. Goeddel,
and
S. Schulz.
Membrane form of guanylate cyclase is an atrial natriuretic peptide receptor.
Nature
338:
78-83,
1989[Medline].
9.
Chomczynski, P.,
and
N. Sacchi.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:
156-159,
1987[Medline].
10.
Currie, M. G.,
D. M. Geller,
B. R. Cole,
G. J. Boylan,
W. Y. Scheng,
S. W. Holmberg,
and
P. Needman.
Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria.
Science
221:
71-73,
1983
11.
De Bold, A. J.,
H. B. Borenstein,
A. T. Veress,
and
H. Sonnenberg.
A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats.
Life Sci.
28:
89-94,
1981[Medline].
12.
Fuller, F.,
J. G. Poter,
A. E. Arfsten,
J. Miller,
J. W. Schilling,
R. M. Scarborough,
J. A. Lewicki,
and
D. B. Shenk.
Atrial natriuretic peptide clearance receptor.
J. Biol. Chem.
263:
9395-9401,
1988
13.
Furaya, M.,
M. Yoshida,
Y. Hayashi,
N. Ohnuma,
K. Minamino,
K. Kangawa,
and
H. Matsuo.
C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells.
Biochem. Biophys. Res. Commun.
177:
927-931,
1991[Medline].
14.
Hirose, S.,
F. Akiyama,
M. Shinjo,
H. Ohno,
and
K. Murakami.
Solubilization and molecular weight estimation of atrial natriuretic factor receptor from bovine adrenal cortex.
Biochem. Biophys. Res. Commun.
130:
574-579,
1985[Medline].
15.
Hughes, R. J.,
R. S. Struthers,
A. M. Fong,
and
P. A. Insel.
Regulation of the atrial natriuretic peptide receptor on smooth muscle cell.
Am. J. Physiol.
253 (Cell Physiol. 22):
C809-C816,
1987
16.
Inagami, T.
Atrial natriuretic factor.
J. Biol. Chem.
264:
3043-3046,
1989
17.
Ishikawa, S.,
T. Saito,
K. Okada,
T. Kuzuya,
K. Kanagawa,
and
H. Matsuo.
Atrial natriuretic factor increases cGMP and inhibits cAMP in rat renal papilla collecting tubule cells in culture.
Biochem. Biophys. Res. Commun.
130:
1147-1153,
1985[Medline].
18.
Koller, K. J.,
D. J. Lowe,
G. L. Bennett,
N. Minamino,
K. Kangawa,
H. Matsuo,
and
D. V. Goeddel.
Selective activation of B natriuretic peptide receptor by C-type natriuretic peptide (CNP).
Science
252:
120-123,
1991
19.
Koller, K. J.,
D. G. Lowe,
N. Minamino,
H. Matsuo,
K. D. Kangawa,
and
D. V. Goeddel.
Differential activation of the human natriuretic peptide receptor guanylyl cyclase.
In: Peptide Regulation of Cardiovascular Function, edited by H. Imura,
H. Matsuo,
and T. Masaki. London: Oxford Univ. Press, 1991, p. 91-99.
20.
Maack, T.,
M. Suzuki,
F. M. Almeida,
D. D. Nussenzveig,
R. M. Scarborough,
G. A. McEncore,
and
J. A. Leiki.
Physiological role of silent receptors of atrial natriuretic factor.
Science
238:
675-678,
1987
21.
Murray, R. D.,
S. Itoh,
T. Inagami,
K. Misono,
S. Seto,
A. G. Scicli,
and
O. A. Carretero.
Effects of synthetic atrial natriuretic factor in isolated perfused rat kidney.
Am. J. Physiol.
249 (Renal Fluid Electrolyte Physiol. 18):
F603-F609,
1985.
22.
Nuglozeh, E.,
G. Gauquelin,
R. Garcia,
J. Tremblay,
and
E. L. Schiffrin.
Atrial natriuretic peptide receptors in renal papilla of DOCA-salt hypertensive rats.
Am. J. Physiol.
259 (Renal Fluid Electrolyte Physiol. 28):
F130-F137,
1990
23.
Ormsbee, H. S.,
and
C. F. Ryan.
Production of hypertension with desoxycorticosterone acetate impregnated silicone rubber implants.
J. Pharmacol. Sci.
62:
255-257,
1973[Medline].
24.
Pandey, K. N.
Kinetic analysis of internalization, recycling and redistribution of atrial natriuretic factor receptor complex in cultured vascular smooth muscle cells.
Biochem. J.
288:
55-61,
1992.
25.
Pandey, K. N.
Stoichiometric analysis of internalization, recycling, and redistribution of photoaffinity-labeled guanylate cyclase/atrial natriuretic factor receptors in cultured murine Leydig tumor cells.
J. Biol. Chem.
268:
4382-4390,
1993
26.
Rosenkranz-Weiss, P.,
W. C. Sessa,
S. Milstein,
S. Kaufman,
C. A. Watson,
and
J. S. Prober.
Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells.
J. Clin. Invest.
93:
2236-2243,
1994.
27.
Schiffrin, E. L.,
and
J. St.-Louis.
Decreased density of vascular receptors for atrial natriuretic peptide in DOCA-salt hypertensive rats.
Hypertension
9:
504-512,
1987
28.
Schulz, S.,
S. Singh,
R. A. Bellet,
G. Singh,
D. J. Tubb,
and
D. L. Garbers.
The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family.
Cell
58:
1155-1162,
1989[Medline].
29.
Stein, B.,
and
H. H. Sussman.
Demonstration of two distinct transferrin receptor recycling pathways and transferrin independent receptor internalization in k562 cells.
J. Biol. Chem.
261:
10319-10331,
1986
30.
Suga, S.,
K. Nakao,
I. Kishimoto,
K. Hosodoa,
M. Mukoama,
H. Arai,
G. Shirakami,
Y. Ogawa,
Komatsu,
O. Nakagawa,
N. Hama,
and
H. Himura.
Phenotype-related alteration in expression of natriuretic peptide receptors in aortic smooth muscle cells.
Circ. Res.
71:
34-39,
1992
31.
Uchida, K.,
T. Mizuno,
M. Shimonaka,
N. Suguira,
K. Nara,
N. Ling,
H. Hagiwara,
and
S. Hirose.
Purification and properties of active atrial natriuretic peptide receptor (type C) from bovine lung.
Biochem. J.
263:
671-678,
1989[Medline].
32.
Yamaguchi, M.,
L. J. Rutledge,
and
D. L. Garbers.
The primary structure of the rat guanylyl cyclase A/atrial natriuretic peptide receptor gene.
J. Biol. Chem.
265:
20414-20420,
1990
33.
Yasunari, K.,
M. Kohno,
K. Murakawa,
K. Yokokawa,
and
T. Takeda.
Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle.
Hypertension
16:
581-586,
1990
34.
Yun, Y.,
C.-Y. A. Chen,
and
A.-B. Shyu.
U-sequence-binding proteins (URBPs) interacting with 20-nucleotide U-rich sequence in the 3' untranslated region of c-fos mRNA may be involved in the first step of c-fos mRNA degradation.
Mol. Cell. Biol.
12:
2931-2940,
1992
This article has been cited by other articles:
![]() |
K. R. Johnson and K. R. Olson Responses of the trout cardiac natriuretic peptide system to manipulation of salt and water balance Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1170 - R1179. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |